MGMaria Mikhailovna Gradinar

Maria Mikhailovna Gradinar

*This is an algorithmically generated author record based on publicly available information.

Maria Mikhailovna Gradinar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Study of drug-drug interactions between Mexidol and thrombolytic drugs

    by A.V. Shchulkin, I.V. Chernykh, Y.V. Abalenikhina, M.V. Gatsanoga, M.M. Gradinar, P.D. Ananyeva, E.N. Yakusheva

    Objective of the study was to investigate the effect of Mexidol on the fibrinolytic activity of Actilyse, Metalyse and Fortelyzin. Material and methods. The study was performed in vitro on blood clots obtained from the blood of wistar rats and healthy donor. The blood clots were incubated with blood plasma for 3 hours at 37 °C to wich Mexidol (0.1, 1, 10 μg/ml), thrombolytics Actilyse (15, 2, 0.5 μg/ml), Metalyse (10, 1, 0.1 μg/ml), Fortelyzin (5, 1.5 and 0.5 μg/ml) or a combination of an antioxidant and thrombolytics were added. To assess the effectiveness of thrombolysis, the % change in blood clotss mass was analyzed, as well as the level of D-dimer in the blood plasma after the end of incubation, which was analyzed by ELISA. Results. Mexidol in all tested concentrations of 0.1—10 μg/ml did not affect the blood clots mass and D-dimer level. Actilyse in concentrations of 15 and 2 μg/ml caused a decrease in blood clots mass by 27.68±9.45% (p<0.0001) and by 15.72±4.38% (p=0.0011), and a concentration of 15 μg/ml also increased the D-dimer concentration compared to the control by 70.9% (p=0.055). Metalyse at a concentration of 10 μg/ml caused a decrease in blood clots mass by 22.53±2.83% (p<0.0001), at a concentration of 1 μg/ml — by 9.57±2.31% (p<0.0001), at a concentration of 0.1 μg/ml — by 3.76±1.04% (p=0.0115). At a concentration of 10 μg/ml, metalyse also caused an increase in the concentration of D-dimer compared to the control by 37.4% (p=0.0022). The combination of actilyse and metalyse with Mexidol in all tested concentrations did not have a reliable effect on the effectiveness of thrombolytics. Fortelyzin in all concentrations did not cause lysis of blood clots obtained from rat blood, but at a concentration of 5 μg/ml it caused a decrease in the mass of blood clots from human blood by 39.69±15.97% (p<0.001), at a concentration of 1.5 μg/ml — by 33.12±2.48% (p=0.001), and at a concentration of 0.5 μg/ml — by 17.79±5.24% (p=0.078). Mexidol in all tested concentrations did not affect the effectiveness of the thrombolytic. Conclusion. The obtained results indicate that Mexidol does not affect the fibrinolytic activity of Actilyse, Metalyse and Fortelyzin.


  • Development and validation of a method for the quantitative determination of rotenone in the homogenate of the cerebral cortex of rats by high-performance liquid chromatography (HPLC)

    by Maria Mikhailovna Gradinar, Alexey Vladimirovich Shchulkin, Ivan Vladimirovich Chernykh, Elena Nikolaevna Yakusheva

    Introduction. Rotenone is a neurotoxin that causes damage of dopaminergic neurons in the substantia nigra and is used as a model for experimental parkinsonian syndrome. The development of a technique for the quantitative determination of rotenone in the brain will allow testing new strategies for the pharmacotherapy of parkinsonism by reducing the penetration of toxic substances into the brain. The aim of the study was to develop and validate an HPLC method for the quantitative determination of rotenone in the cerebral cortex of rats. Material and methods. Quantitative determination of rotenone was carried out using a Stayer chromatographic system (Аквилон, Russia) with a UV spectrophotometric detector UVV 104 at a wavelength of 296 nm in isocratic mode. A reverse-phase chromatographic column Luna C18 100Å (250*4.6) with a grain size of 5 μm at a temperature of 37°C was used. The composition of the mobile phase was deionized water, acetonitrile in a ratio of 70:30. Determination of rotenone concentration was carried out by the method of absolute calibration by the area of the peaks. Sample preparation consisted in homogenization of 500 mg of crushed frontal lobe of the rat cerebral cortex in 500 μl of purified water, followed by centrifugation (1750 g), collection of the supernatant and sedimentation of the proteins by acetonitrile. The liquid layer was evaporated on a rotary vacuum. 250 µl of the mobile phase was added to the dry residue, and 100 µl was injected into the chromatograph. Results. The method was validated for the following parameters: selectivity, linearity, accuracy, precision, limits of detection and determination, sample transfer, sample stability. The analytical range was 62.5−1000.0 ng/g brain with a correlation coefficient of more than 0.99. The limits of detection and quantification of rotenone were 25.0 and 62.5 ng/g, respectively. The calculation of intra- and inter-cycle accuracy and precision showed that these parameters do not exceed 20% for the concentration corresponding to the lower limit of quantitative determination, and 15% for higher concentrations. The stability of the technique was demonstrated during short-term storage at room temperature, three freeze-thaw cycles at –80°C, and storage at –80°C for 60 days. There was no sample transfer. Limitations. The chromatographic technique makes it possible to analyze the content of rotenone in the cerebral cortex of rats in the concentration range of 62.5–1000.0 ng/g. Conclusion. A method for the quantitative determination of rotenone in the homogenate of the cerebral cortex of rats has been developed and validated.

  • Open Access

    Role of P-glycoprotein in the pharmacotherapy of pregnant women

    by N. M. Popova, A. V. Shchulkin, I. V. Chernykh, A. S. Esenina, M. M. Gradinar, E. N. Yakusheva

    This review addresses the function of the protein-transporter glycoprotein-P (Pgp, ABCB1 protein) and the expression of its encoding gene MDR1/mdr1 throughout the gestational period in humans and animals. We discuss the relationship between the transporter function and the hormone fluctuations during pregnancy. We cite studies on the association between the MDR1/mdr1 gene polymorphisms and the hemato-placental barrier permeability for Pgp substrates, as well as fetal malformations. Under a separate section, drugs commonly used in pregnant women are characterized in terms of their roles as substrates, inducers or inhibitors of the Pgp transporter.

  • Open Access

    Functional activity of p-glycoprotein in blood-brain barrier during experimental par-kinson's syndrome

    by Ivan V. Chernykh, Aleksey V. Shchulkin, Pavel Yu. Mylnikov, Maria V. Gatsanoga, Maria M. Gradinar, Anna S. Yesenina, Elena N. Yakusheva, Щулькин Алексей Владимирович, Гацанога Мария Валериевна

    Background. P-glycoprotein (Pgp, ABCB1-protein) is a membrane transporter with broad substrate specificity that is localized in hepatocytes, enterocytes, epithelial renal tubules, and also in tissue barriers, including blood-brain barrier (BBB). Increased Pgp activity in BBB is one of the reasons for the pharmacoresistance of a number of CNS diseases. Aim. Analysis of Pgp functional activity in BBB during experimental Parkinson's syndrome. Materials and Methods. The work was performed on 90 Wistar rats, divided into 3 series (n=30 in each). The 1 series (control) was subcutaneously injected sunflower oil once a day for 7 days, and Pgp activity in BBB was assessed on the 8th day. The 2 and 3 series (pathology control) - were administered rotenone at a dose of 2.5 mg/kg once a day for 7 and 28 days respectively to simulate parkin-sonism. At the end of the experiment Pgp activity was estimated. To confirm Parkinson's syndrome, in addition to the clinical picture, level of dopamine in midbrain and striatum was determined using enzyme-linked immunosorbent assay. Pgp functional activity in BBB was assessed by the degree of penetration of its marker substrate fexofenadine into the brain after its intravenous administration at a dose of 10 mg/kg. The content of fexofenadine in the blood plasma and in brain tissue was estimated by the area under pharmacokinetic curve of the substance (in the blood or brain tissues) - AUC0-t(plasma) or AUC0-t(brain) respectively. To assess the BBB permeability the ratio AUC0-t(brain) / AUC0-t(plasma) was calculated. Results. Rotenone administration led to the development of parkinsonism typical picture: muscle stiffness, hypokinesia, gait instability. There was a decrease in dopamine level in the striatum after 7 days by 69.6% (p=0.095), after 28 days - by 93.9% (p=0.008), in midbrain - by 72.7% (p=0.095) and 68.7% (p=0.032) respectively. Fexofenadine AUC0-t(plasma) and AUC0-t(brain) after its intravenous administration to control rats were 266.2 (246.4; 285.6) μg/ml*min and 5.9 (5.8;6.6) µg/g*min respectively, AUC0-t(brain) /AUC0-t(plasma) - 0.020 (0.019; 0.022). When rotenone was for 7 days administered - fexofenadine AUC0-t(brain) increased 2.02 times (p=0.0163), AUC0-t(brain) / AUC0-t(plasma) - 2.4 times (p=0.0283). 28 days administration of rotenone led to augmentation of AUC0-t(brain) of fexofenadine by 1.75 times (p=0.0283), AUC0-t(brain) / AUC0-t(plasma) - by 2.27 times (p=0.0163). Conclusions. The development of Parkinson’s syndrome, caused by the administration of rotenone, inhibits Pgp functional activity in BBB, which is confirmed by the accumulation in the brain marker substrate of the transporter - fexofenadine.


  • Open Access

    P-glycoprotein functional activity in «soviet chinchilla» rabbits during pregnancy

    by Natalia M. Popova, Aleksey V. Shchulkin, Ivan V. Chernykh, Anna S. Esenina, Maria M. Gradinar, Larisa V. Nikiforova, Alexander N. Ryabkov, Elena N. Yakusheva, Шулькин Алексей Владимирович, Рябков Александр Николаевич

    P-glycoprotein (Pgp, ABCB1-protein) is a membrane transporter protein that plays the key role in pharmacokinetics of drugs with a broad spectrum of action. Substrates of this transporter are some medical drugs (antibacterial, antiretroviral, hypotensive) that are prescribed to pregnant women for long-term intake, sometimes throughout the whole gestation period. Aim to study the activity of Pgp on the organism level in rabbits of Soviet Chinchilla breed in pregnancy. Materials and Methods. The study was performed on 21 Soviet Chinchilla female rabbits (3000-3500 g). The animals were divided into 3 series. The first series (n=6) included rabbits with 7 days of pregnancy; the second series (n=5) - animals with 14 days of pregnancy; the third series (n=10) - rabbits with 21 days of pregnancy. 7 Days before the study and in the indicated gestation periods, functional activity of Pgp was assessed by the pharmacokinetics of marker transporter substrate – fexofenadine, after its single oral introduction (67.5 mg/kg). Besides, serum concentrations of progesterone, estradiol, testosterone and prolactin were determined by radio immune method Results. In all the studied gestational periods, serum concentrations of estradiol, testosterone and prolactin did not significantly differ from those before pregnancy, but the level of progesterone in blood serum was significantly elevated above the norm. On the 7th day of pregnancy pharmacokinetic parameters of fexofenadine did not show any reliable changes as compared to the initial va-lues. On the 14th day of pregnancy a reliable increase in Cmax, AUC0-t, T1/2 of fexofenadine was noted as compared to the parameters before pregnancy, which indicates a decrease in Pgp functional activity on the organism level. On the 21st day of pregnancy Cmax of fexofenadine remained elevated. Other pharmacokinetic parameters of fexofenadine did not show reliable changes. Conclusion. Reduction in Pgp functional activity, determined by the pharmacokinetics of its marker substrate (fexofenadine), was noted in rabbits of Soviet Chinchilla breed on the 14th and 21st days of pregnancy with the underlying significant increase in progesterone level.